|Bid||93.40 x 400|
|Ask||99.50 x 500|
|Day's Range||96.18 - 99.44|
|52 Week Range||96.18 - 157.02|
|PE Ratio (TTM)||46.55|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||159.53|
Doug Kass shares his thoughts on trying to explain that which cannot be explained, and also discusses what was good (and bad and ugly) this week.
Analysts at Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Thursday despite the stock's 17-percent loss year to date and two management shake-ups in the past six months alone. Morgan ...
Shares of Alexion Pharmaceuticals (ALXN) have been hammered the past two days after its new CEO cleaned house. But has it fallen too far? Investors, it seems, worry that the decision to replace much of ...